Clinical trial
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid…
NCT00193570 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193570 |
|---|---|
| Title | Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors |
| Official title | A Phase I Study of Topotecan in Combination With Docetaxel in Patients With Refractory and/or Advanced Solid Tumors |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | GlaxoSmithKline Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Topotecan, Docetaxel |
| Enrollment | 20 |
| Start date | Feb 1, 2002 |
| Primary completion | Aug 1, 2004 |
| Completion | Jan 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 23, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: